Laidlaw’s James Ahern Named to Crain’s New York Notable Leaders in Finance 2024dan2024-03-26T20:20:57-04:00March 26th, 2024|Read More
EyePoint Pharmaceuticals Announces Closing of Upsized Public Offering and Full Exercise of Option to Purchase Additional Sharesdan2023-12-12T18:34:27-05:00December 12th, 2023|Read More
Laidlaw served as Co-Manager on the $129,000,000 Common Stock and Concurrent Private Placement for Soleno Therapeutics (SLNO)dan2023-12-05T23:49:34-05:00December 5th, 2023|Read More
Laidlaw acts as Co-Manager on the $287,500,000 Follow-On Offering for Viking Therapeutics.dan2023-03-31T03:30:28-04:00March 31st, 2023|Read More
Laidlaw acts as Exclusive Introducing Broker on NLS Pharmaceutics’ Closing of Initial Tranche of US$10.0 Million Purchase Agreement with BVF Partners L.P.dan2022-12-19T05:42:02-05:00December 19th, 2022|Read More
Stay In Touch